Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens
Teppei Yamada(Harvard University), Kyogo Itoh(Kurume University), Shinjiro Sakamoto(Kurume University), Kayoko Waki(Frederick National Laboratory for Cancer Research), Koichi Yoshiyama(Kurume University), Nobukazu Komatsu(Kurume University), Shinzo Takamori(Kurume University), Yasuhiro Terazaki(Kurume University), Akihiko Kawahara(Kurume University), Satoko Matsueda(Kurume University), Tetsuro Sasada(Kanagawa Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Yuichi Yamashita(Fukuoka University Hospital), Masayoshi Kage(Junshin Gakuen University), Akira Yamada(Fujita Health University)
Cited by 14
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695